Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)-Reference-Cited by-同舟云学术

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Published:2020-06-08 Issue:1 Volume:35 Page:135-142
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J. Eur. Acad. Dermatol. Venereol.

Author:

Bagel J.¹^ORCID,Blauvelt A.²^ORCID,Nia J.³,Hashim P.³,Patekar M.⁴,Vera A.⁴,Ahmad K.⁵,Paguet B.⁴,Xia S.⁶,Muscianisi E.⁷,Lebwohl M.³

Affiliation:

1. Psoriasis Treatment Center of Central New Jersey East Windsor NJ USA

2. Oregon Medical Research Center Portland OR USA

3. Icahn School of Medicine at Mount Sinai New York NY USA

4. Novartis Pharma AG Basel Switzerland

5. Novartis Healthcare Pvt Ltd Hyderabad India

6. Beijing Novartis Pharma Co, Ltd Shanghai China

7. Novartis Pharmaceuticals Corporation East Hanover NJ USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16558

Reference35 articles.

1. Research gaps in psoriasis: Opportunities for future studies

2. Etanercept as Monotherapy in Patients with Psoriasis

3. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

4. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

5. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective;PLOS ONE;2024-09-06

2. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

3. Biomarkers and biologics related with psoriasis and psoriatic arthritis;International Immunopharmacology;2023-09

4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12

5. Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration;Journal of Clinical Medicine;2023-06-12